ストックスクリーナーアプリを入手
2.96
0.34%
0.010
アフターアワーズ：
2.96
前日終値:
$2.95
開ける：
$2.98
24時間の取引高:
211.68K
Relative Volume:
0.69
時価総額：
$145.18M
収益：
$226.63M
当期純損益:
$15.38M
株価収益率:
-59.20
EPS:
-0.05
ネットキャッシュフロー:
$35.61M
1週間 パフォーマンス:
+6.09%
1か月 パフォーマンス:
+11.70%
6か月 パフォーマンス:
-39.09%
1年 パフォーマンス:
+6.47%
1日の値動き範囲:
$2.91
$3.03
1週間の範囲:
$2.765
$3.04
52週間の値動き範囲:
$2.225
$7.73
Puma Biotechnology Inc Stock (PBYI) Company Profile
名前
Puma Biotechnology Inc
セクター
電話
(424) 248-6500
住所
10880 WILSHIRE BLVD., LOS ANGELES, CA
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-09-28 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Underperform |
| 2019-10-08 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-10 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-01-17 | 開始されました | Leerink Partners | Mkt Perform |
| 2019-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2018-11-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-11-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-17 | 開始されました | Goldman | Sell |
| 2018-05-11 | 繰り返されました | Stifel | Buy |
| 2017-11-10 | 繰り返されました | Citigroup | Buy |
| 2017-11-10 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | 繰り返されました | Stifel | Buy |
| 2017-09-11 | 繰り返されました | Credit Suisse | Outperform |
| 2017-07-10 | 再開されました | Leerink Partners | Outperform |
| 2017-06-06 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | 繰り返されました | RBC Capital Mkts | Sector Perform |
すべてを表示
Puma Biotechnology Inc (PBYI) 最新ニュース
Puma Biotechnology (NASDAQ:PBYI) Raised to "Strong-Buy" at StockNews.com - MarketBeat
Puma Biotechnology (PBYI) Set to Announce Quarterly Earnings on Thursday - MarketBeat
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GlobeNewswire
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ - The Bakersfield Californian
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - BioSpace
Puma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at StockNews.com - MarketBeat
What is Zacks Research's Forecast for PBYI FY2026 Earnings? - MarketBeat
Equities Analysts Offer Predictions for PBYI Q3 Earnings - MarketBeat
With A Return On Equity Of 18%, Has Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Management Done Well? - Yahoo Finance
Puma Biotechnology quickly drops after patents for Tagrisso ruled invalid - MSN
FY2025 EPS Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) Decreased by Zacks Research - MarketBeat
Frazier Life Sciences Management L.P. Purchases 246,264 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Affinity Asset Advisors LLC Makes New $815,000 Investment in Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Fred Alger Management LLC Raises Stake in Hamilton Lane Incorporated (NASDAQ:HLNE) - MarketBeat
Hsbc Holdings PLC Has $4.29 Million Position in Grupo Financiero Galicia S.A. (NASDAQ:GGAL) - MarketBeat
The growth track for Humacyte Inc (HUMA) has changed recently - SETE News
Humacyte: Navigating The FDA Uncertainty And ATEV’s Potential (NASDAQ:HUMA) - Seeking Alpha
Puma VCT 13 Launches £70M Share Offer - TipRanks
HUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.38 - MarketBeat
It is Poised to be a Bull Market for Puma Biotechnology Inc (PBYI) - SETE News
American Century Companies Inc. Sells 186,924 Shares of Foot Locker, Inc. (NYSE:FL) - Defense World
Bank of America Raises Trupanion (NASDAQ:TRUP) Price Target to $56.00 - MarketBeat
Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter
Insider Selling: Sebelius Kathleen, Humacyte Inc [HUMA] Director divested 5,182 shares - Knox Daily
A$AP Rocky’s Lineup of Puma Sneakers Is Quickly Growing Bigger - Yahoo! Voices
Achilles gains on plans to explore strategic options - XM
Achilles Therapeutics Shares Are Trading Higher: What You Need To Know - Benzinga
Puma VCT 13 PLC Executes Share Buyback - TipRanks
A$AP Rocky’s Distressed PUMA Inhale Is Dropping In “Pop Red” - Sneaker News
A$AP Rocky's PUMA Inhale Distressed Appears in Black and Red - HYPEBEAST
A$ap Rocky x Puma Inhale Distressed Black / Pop RedSep 2024402453-01 - KicksOnFire.com
Puma Biotech's patent suit sees mixed verdict By Investing.com - Investing.com Australia
Upward Trajectory: Humacyte Inc (HUMA) Posts a Slidee, Closing at 5.28 - The Dwinnex
Puma Biotechnology rises on appeal of AstraZeneca Tagrisso patent dispute - MSN
Puma Biotech's patent suit sees mixed verdict - Investing.com
Humacyte Inc (HUMA) can make a big difference with a little luck - SETE News
Puma Biotechnology (NASDAQ:PBYI) investors are sitting on a loss of 79% if they invested five years ago - Yahoo Finance
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment? - Simply Wall St
Puma Biotechnology Inc [NASDAQ: PBYI] Sees Decrease in Stock Value - Knox Daily
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - sharewise
Financial Analysis: Puma Biotechnology Inc (PBYI)’s Ratios Unveil Key Insights - The Dwinnex
Was there any good news for Puma Biotechnology Inc (PBYI) stock in the last session? - US Post News
Q1 2026 EPS Estimates for Puma Biotechnology, Inc. Boosted by Analyst (NASDAQ:PBYI) - MarketBeat
Zacks Research Analysts Decrease Earnings Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Market Momentum: Puma Biotechnology Inc (PBYI) Registers a 4.33 Increase, Closing at 2.65 - The Dwinnex
Puma Biotech confirms court ruling on patent invalidity, disagrees with verdict - MSN
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop - Simply Wall St
Puma Biotech patent claims partially invalidated in court - Investing.com
Puma Biotech patent claims partially invalidated in court By Investing.com - Investing.com India
Puma Biotech confirms court ruling on patent dispute with AstraZeneca - Seeking Alpha
Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso - MSN
Puma Biotechnology Inc (PBYI) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):